42nd week of 2021 patent applcation highlights part 25 |
Patent application number | Title | Published |
20210323958 | 5-METHYL-4-FLUORO-THIAZOL-2-YL COMPOUNDS - The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating neurodegenerative diseases, such as Alzheimers disease. | 2021-10-21 |
20210323959 | METHODS FOR PURIFYING ISAVUCONAZONIUM SULFATE - The invention provides methods for purifying isavuconazonium sulfate comprising the steps of —(a) providing a mixture comprising the sulfate salt of the compound of formula (I) and an aliphatic alcohol, wherein the pH of the mixture is in the range of about pH 1 to about pH 6; —(b) allowing a first portion of the sulfate salt of the compound of formula (I) to crystalize from the mixture; and —(c) adding an aprotic organic solvent to the mixture and allowing an additional portion of the sulfate salt of the compound of formula (I) to precipitate from the mixture. | 2021-10-21 |
20210323960 | FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR - Provided is a fused tri-cyclic compound as PDE3/PDE4 dual inhibitor, and a use thereof in the preparation of drugs for PDE3/PDE4 associated diseases, particularly in medicinal functions such as chronic obstructive pulmonary disease (COPD). Provided are specifically a compound of formula (I) and a pharmaceutically acceptable salt thereof. | 2021-10-21 |
20210323961 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: | 2021-10-21 |
20210323962 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS - Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N−1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed. | 2021-10-21 |
20210323963 | Functional Materials Based on Stable Chemical Structure - A series of novel donor-acceptor type TADF luminogens have been designed with the aim of developing stable OLEDs with enhanced operational stability and improved color purity. These materials can be utilized in full color displays and lighting applications. | 2021-10-21 |
20210323964 | POLYMORPHS - The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament. | 2021-10-21 |
20210323965 | SMALL-MOLECULE HSP90 INHIBITORS - Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands. | 2021-10-21 |
20210323966 | IMIDAZOPYRIDAZINE COMPOUNDS - Compounds of formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. | 2021-10-21 |
20210323967 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - The compound | 2021-10-21 |
20210323968 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound containing indolocarbazole having a formula: | 2021-10-21 |
20210323969 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION - A compound and/or a pharmaceutically acceptable salt thereof has the following formula A: | 2021-10-21 |
20210323970 | METHOD FOR PRODUCING A SPIROOXINDOLE DERIVATIVE - The present disclosure provides a method for efficiently producing and providing compounds having a spirooxindole skeleton, for example compounds having a spirooxindole skeleton and having antitumor activity that inhibit the interaction between Mdm2 protein and p53 protein, or intermediates thereof, using an asymmetric catalyst. Compounds having optically active tricyclic dispiroindole skeletons are obtained through catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a Lewis acid. | 2021-10-21 |
20210323971 | SYNTHESIS METHODS FOR UPADACITINIB AND INTERMEDIATE THEREOF - The present disclosure relates to a JAK inhibitor upadacitinib intermediate and a preparation method therefor, and to a preparation method for a JAK inhibitor upadacitinib. The upadacitinib intermediate of the present application is as shown in Formula (II) or Formula (III), | 2021-10-21 |
20210323972 | CRYSTALS OF PYRANODIPYRIDINE COMPOUND - The present invention provides a crystal of the compound represented by formula (I) having applicability as a drug substance of pharmaceuticals. | 2021-10-21 |
20210323973 | DIELS-ALDER REACTION WITH FURANICS TO OBTAIN AROMATICS - The present invention is directed to the preparation of phthalic anhydride compounds and the intermediate phthalide compounds. In particular, the invention is directed to an improved bio-based route from furanic compounds to phthalic anhydride compounds by reacting furfuryl alcohol (i.e. 2-hydroxymethylfuran) or an analogue thereof having a nucleophilic atom on the 2-methyl, with a dienophile comprising an α,β-unsaturated carbonyl comprising an α′-leaving group. The inventions further involved preparation of phthalic anhydride compounds, phthalic acid compounds and reduction products of the intermediate phthalide compounds. | 2021-10-21 |
20210323974 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE INCLUDING SAME - The present specification relates to a heterocyclic compound represented by Formula 1, an organic electronic device including the heterocyclic compound in an organic active layer, and a method for manufacturing the organic electronic device. | 2021-10-21 |
20210323975 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS - The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments. | 2021-10-21 |
20210323976 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION - Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein. | 2021-10-21 |
20210323977 | PYRROLIDINYL AMIDE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE - The present invention relates to compounds of formula (I) wherein R | 2021-10-21 |
20210323978 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS - The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: | 2021-10-21 |
20210323979 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF - The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof. | 2021-10-21 |
20210323980 | BICYCLIC HETEROARYL DERIVATIVES - The invention provides new bicyclic heteroaryl compounds having the general formula (I) wherein R | 2021-10-21 |
20210323981 | FREE AMINO COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION - The present invention relates to novel compounds of formula (I), | 2021-10-21 |
20210323982 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER - The invention relates to compounds of formula (I): | 2021-10-21 |
20210323983 | STABLE SILYLATING REAGENTS - The present disclosure is directed to methods of silylating organic substrates containing C—H or O—H bonds. In some embodiments, the methods use compositions that are derived from the preconditioning of mixtures of hydrosilanes or organodisilanes with bases, including metal hydroxide, metal alkoxide, metal silanoates, potassium amides, and/or graphitic potassium bases. | 2021-10-21 |
20210323984 | POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS - New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes. | 2021-10-21 |
20210323985 | SHIELDING AGENTS AND THEIR USE - The present disclosure relates to compounds useful as shielding agents for PSMA therapies. The present disclosure relates to methods of treating PSMA expressing cancers with one or more radiotherapeutics agents in combination with one or more shielding agents. The present disclosure relates to methods of imaging using one or more imaging agents containing a radionuclide in combination with one or more shielding agents. The present disclosure also relates to methods of making shielding agents. | 2021-10-21 |
20210323986 | IRIDIUM COMPLEX COMPOUND - An iridium complex compound represented by formula (5). Provided is an iridium complex compound that is useful as a material for a light-emitting layer of an organic electroluminescent element, has a narrow half-width of the emission spectrum thereof, has high solubility in a solvent, and has a short wavelength that is not too long and is suitable as a red-light-emitting material. | 2021-10-21 |
20210323987 | Methods for the Synthesis of Heteroatom Containing Polycyclic Aromatic Hydrocarbons - Methods for the synthesis of polycyclic aromatic hydrocarbons and synthesis platforms for performing such syntheses are provided. Methods and platforms are provided that allow for the synthesis of aza-polycyclic aromatic hydrocarbons by an expedient ring assembly. Methods and platforms allow for a modular approach to synthesis that provide multiple new C—C bonds in sequential pericyclic reactions, thus giving access to compounds with multiple axes of substitution. | 2021-10-21 |
20210323988 | Potassium Humate Zinc Sulfate Compound - A process for making a potassium humate zinc sulfate compound, the process including: obtaining a plurality of fully-soluble potassium humate powder particles; obtaining a zinc sulfate compound; and mixing the plurality of potassium humate particles with the zinc sulfate compound, thereby forming a homogenized mixture, thereby forming a potassium humate zinc sulfate compound configured to be applied to a soil surface. | 2021-10-21 |
20210323989 | METHOD AND AN APPARATUS FOR FORMING A LIGNIN FRACTION, A LIGNIN COMPOSITION AND ITS USE - The invention relates to a method and an apparatus for forming a lignin fraction from crude lignin which has been processed by means of a treatment step selected from enzymatic treatment, treatment with ionic liquid and their combinations. The method comprises treating the crude lignin ( | 2021-10-21 |
20210323990 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS - Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, highly potent multimeric E-selectin antagonist are dessorbed and pharmaceutical compositions comprising at least one of the same. | 2021-10-21 |
20210323991 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS - The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions. | 2021-10-21 |
20210323992 | GEMCITABINE PRODRUGS - Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer. | 2021-10-21 |
20210323993 | Compounds Useful in HIV Therapy - The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects. | 2021-10-21 |
20210323994 | Methods for Isolation, Identification, and Quantification of miRNAs - Method and compositions and kits for isolation, identification, and quantification of miRNAs and other small RNAs, including but not limited to, siRNAs, mRNAs, and snRNAs are disclosed. Methods of diagnosing a disease or its progression are also disclosed. | 2021-10-21 |
20210323995 | ISOLITHOCHOLIC ACID OR ISOALLOLITHOCHOLIC ACID AND DEUTERATED DERIVATIVES THEREOF FOR PREVENTING AND TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASES - The present invention relates to isolithocholic acid (3ß-hydroxy-5ß-cholan-24-oic acid, iso-LCA) and isoallolithocholic acid (3ß-hydroxy-5α-cholan-24-oic acid) and their deuterated analogs for preventing or treating | 2021-10-21 |
20210323996 | COMPOSITIONS AND METHODS FOR PROFILING OF GUT MICROBIOTA-ASSOCIATED BILE SALT HYDROLASE (BSH) ACTIVITY - A composition having the following structure: | 2021-10-21 |
20210323997 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS - Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: | 2021-10-21 |
20210323998 | C19 SCAFFOLDS AND STEROIDS AND METHODS OF USE AND MANUFACTURE THEREOF - The present disclosure relates to stereodefined polycyclic (e.g., tetracyclic) compounds that contain quaternary centers at one or multiple ring fusions, synthetic methods for preparing such compounds, and methods of using such compounds to treat a disease, such as a brain tumor and, particularly, a glioma. | 2021-10-21 |
20210323999 | PROTEIN PURIFICATION - The present invention relates to a process for purification a protein comprising a semi-continuous chromatography step whereby the flow-through is collected and re-loaded onto the chromatography matrix. | 2021-10-21 |
20210324000 | METHODS OF INACTIVATING VIRAL CONTAMINANTS - The present invention relates to a method for preparing an antibody-containing solution free of viral contaminants starting from cultured cells are described. The method include a step of subjecting the antibody containing solution to a mix of solvent and detergent or to high pH. | 2021-10-21 |
20210324001 | NEW PURIFICATION METHOD - Methods of purifying a peptide are provided. Also provided is an improved method of purifying a polypeptide of interest from a sample containing the polypeptide of interest and impurities in which clarification and the first purification step are part of one step only. | 2021-10-21 |
20210324002 | TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY - The present disclosure relates to tertiary amino lipidated and/or PEGylated cationic peptide compounds and complexes thereof with nucleic acids for endocellular delivery, methods for preparing the compounds and complexes, and methods for delivering polyanionic compounds to cells. | 2021-10-21 |
20210324003 | SIV ENVELOPE TRIMER - The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-1 vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies. The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention. | 2021-10-21 |
20210324004 | Peptides for the Treatment of COVID-19 - Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed. | 2021-10-21 |
20210324005 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof - This application describes a family of compounds acting as β-arrestin effectors that can be used, for example, for treating acute respiratory distress syndrome, for preventing and treating thrombosis, platelet adhesion, and platelet aggregation, and/or for reducing a D-Dimer response, in a subject with ARDS or a viral infection, such as a coronavirus infection. | 2021-10-21 |
20210324006 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY - The present invention relates to compositions comprising and methods for use of novel synthetic peptide antagonists. Antagonists of the invention inhibit the binding of acetylcholine to the muscle-type nicotinic acetylcholine receptor. They are useful in, e.g., cosmetics and pharmaceuticals that prevent or improve the appearance of undesirable skin features including wrinkles. | 2021-10-21 |
20210324007 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN - There is described herein, multimers comprising plurality of compounds covalently linked together, the compounds independently being of formula (I). | 2021-10-21 |
20210324008 | CRYSTALLINE FORM OF COMPOUND AND USES THEREOF IN MEDICINE - A crystalline form A of the compound having formula (I) and uses thereof in medicine are described. Specifically, it relates to crystalline form A and pharmaceutically compositions thereof. Furthermore, it relates to the uses of crystalline form A disclosed herein and pharmaceutically compositions thereof disclosed herein in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis C vims (HCV) infection. | 2021-10-21 |
20210324009 | ANTI-BACTERIAL CALCIUM-DEPENDENT ANTIBIOTIC (CDA) ANALOGS AND METHODS OF TREATING BACTERIAL INFECTIONS - Provided herein are calcium-dependent antibiotics (CDAs), as a novel therapeutic target for treating bacterial infections. The present invention also relates to pharmaceutical compositions comprising such compounds, and to methods of use thereof for combating bacteria and treating bacterial infections. | 2021-10-21 |
20210324010 | FUSION PRODUCTS AND BIOCONJUGATES CONTAINING MIXED CHARGE PEPTIDES - Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, which results in a better therapeutic efficacy compared to an active protein alone. Thus, a fusion protein or a conjugate of the disclosure can be useful in developing a protein or peptide drug, treating or preventing diseases, disorders, or conditions, or improving a subjects health or wellbeing. | 2021-10-21 |
20210324011 | SELF-ASSEMBLING PROTEIN HOMO-POLYMERS - Disclosed herein are polypeptides having the amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of the amino acid sequence selected from the group consisting of SEQ ID NO: 1-33 and 36, wherein the polypeptides include at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the identified interface residues, and wherein the polypeptides are capable of end-to-end homo-polymerization, homo-polymers of the polypeptides, and related capping and anchor proteins to facilitate homo-polymer formation. | 2021-10-21 |
20210324012 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS - The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA. | 2021-10-21 |
20210324013 | MATURE VIRUS-LIKE PARTICLES OF FLAVIVIRUSES - The present disclosure associates to a modified and expressed virus-like particles. Particularly, the virus-like particle is capable of eliciting immune response in a mammal upon administrating a pharmaceutically efficient dosage to the mammal. The virus-like particle comprises a modified form of M and E structural proteins of flavivirus. Further, the virus-like particle comprises an amino acids sequence substantially corresponding to a sequence setting forth in SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4, wherein conserved and internally located His at multiple positions of the M and E proteins are substituted with uncharged residues, and other secretion-enhancing substitutions are introduced. | 2021-10-21 |
20210324014 | A NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS - Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof. | 2021-10-21 |
20210324015 | COVALENTLY FUSED VIRAL COAT PROTEINS FOR THE DISPLAY OF TARGET MOLECULES - A fusion protein comprising a target protein, a first recombinant viral coat protein, a second recombinant viral coat protein and a first linkage peptide is provided. The target protein is at N-terminus of the first recombinant viral coat protein. The first recombinant viral coat protein is linked to N-terminus of the first linkage peptide. The second recombinant viral coat protein is linked to C-terminus of the first linkage peptide. The first and second recombinant viral coat proteins are derived from the coat protein (CP) of alfalfa mosaic virus (AIMV). The fusion protein may further comprise a second linkage peptide between the target protein and the first recombinant viral coat protein. The fusion protein may form a virus like particle (VLP). The target protein may be displayed on the surface of the VLP. Also provided are methods for producing the fusion protein and the VLP as well as the uses of the fusion protein and/or the VLP. | 2021-10-21 |
20210324016 | RECOMBINANT VACCINE AGAINST MAREK'S DISEASE AND NEWCASTLE DISEASE - Provided herein are immunogenic compositions containing recombinant viruses capable of inducing protection in poultry against both Marek's disease virus (MDV) and Newcastle disease virus (NDV). Such viruses incorporate nucleic acids for expressing at least one MDV antigen, such as glycoprotein B, and antigenic portions thereof, in a recombinant NDV genome. | 2021-10-21 |
20210324017 | GLYCOSYLATED COMP PILIN VARIANTS, METHODS OF MAKING AND USES THEREOF - Provided herein are glycosylated ComP proteins, fragments and fusion proteins thereof, and methods of making, for example, for use in the production of conjugate vaccines. Also provided herein are conjugate vaccines against diseases including bacterial diseases. | 2021-10-21 |
20210324018 | MUTANT STRAIN OF TRICHODERMA REESEI AND METHOD OF PRODUCING PROTEIN USING SAME - A mutant strain of | 2021-10-21 |
20210324019 | DNA-BINDING PROTEIN USING PPR MOTIF, AND USE THEREOF - The object of the present invention is to, by analyzing PPR proteins that act to bind to DNA with a prediction that RNA recognition rules of PPR motifs can also be used for recognition of DNA, find a PPR protein showing such a characteristic. According to the present invention, it was revealed that, with a protein that can bind in a DNA base-selective manner or a DNA base sequence-specific manner, which contains one or more, preferably 2 to 30, more preferably 5 to 25, most preferably 9 to 15, of PPR motifs having a structure of the following formula 1 (wherein, in the formula 1, Helix A is a part that can form an α-helix structure; X does not exist, or is a part consisting of 1 to 9 amino acids; Helix B is a part that can form an α-helix structure; and L is a part consisting of 2 to 7 amino acids), and having a specific combination of amino acids corresponding to a DNA base or DNA base sequence as amino acids of three positions of No. 1 A.A., No. 4 A.A., in Helix A of the formula 1 and No. “ii” (-2) A.A. contained in L of the formula 1, the aforementioned object could be achieved. | 2021-10-21 |
20210324020 | MUTANT LYSENIN PORES - The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin. | 2021-10-21 |
20210324021 | NOVEL THRERAPY FOR ACUTE DAMAGE TO LUNG TISSUE - Embodiments of the disclosure provide a method for treatment of damaged lung tissue, e.g., lungs of a patient with a viral infection (e.g., coronavirus) and/or a bacterial infection and/or a parasitic pathogen or a patient whose lung tissue was damaged by exposure to a chemical, and a patient with acute respiratory distress syndrome (ARDS). Also provided is a method for protecting the brain from neuro-invasion and preventing inflammatory damage to organs remote from the lungs, by blocking cytokine synthesis in the lungs. The treatment includes administering a leptin antagonist (LepA) locally to the upper airways and/or to the lungs of the patient. Typically, the LepA is administered in an inhalable composition, such as, an aerosol. | 2021-10-21 |
20210324022 | CELL-PENETRATING CEREBLON RECOMBINANT FUSION PROTEIN AND USE THEREOF - The present invention relates to a novel cell-penetrating recombinant fusion protein including a peptide domain consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide domain consisting of the amino acid sequence of SEQ ID NO: 2. The novel cell-penetrating cereblon recombinant fusion protein according to the present invention may be usefully employed in the prevention or treatment of cereblon-related diseases. | 2021-10-21 |
20210324023 | MODULATING IMMUNE RESPONSES - Modulators of STING are able to upregulate or down regulate immune responses. Administration of such modulators can be used to treat diseases or other undesirable conditions in a subject either directly or in combination with other agents. | 2021-10-21 |
20210324024 | ENGINEERED SEMAPHORINS AND USES THEREOF - Provided herein are methods and compositions comprising or using mutant semaphorin polypeptides. | 2021-10-21 |
20210324025 | COMPOSITIONS AND METHODS FOR TREATING CORNEAL ENDOTHELIUM - Compositions of proteoglycans and core proteins thereof and related methods of treating subjects, e.g., patients, are described. The method may include applying a composition to an eye of a subject before, during, and/or after an intraocular medical procedure. The composition may comprise a proteoglycan or core protein thereof, such as decorin proteoglycan or decorin core protein, and a pharmaceutically-acceptable salt. The composition may be in the form of an aqueous solution, viscoelastic gel, or viscoelastic film, for example. Further methods are described that include treating donor corneal tissue with a composition comprising a proteoglycan or core protein thereof. The treated donor corneal tissue may be used as or in a corneal graft, such as during endothelial keratoplasty. | 2021-10-21 |
20210324026 | MODIFIED IMMUNOMODULATORY PEPTIDE - Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders. | 2021-10-21 |
20210324027 | MODIFIED INTERLEUKIN-7 PROTEINS AND USES THEREOF - Provided are a modified IL-7 polypeptide and a fusion protein containing the modified IL-7 polypeptide. The fusion protein of the modified IL-7 includes: a first domain containing an interleukin-7 polypeptide; a second domain containing an oligopeptide having 1 to 10 amino acid residues (with proviso that the second domain excludes the oligopeptide consisting of methionine and/or glycine); and (c) a third domain which prolongs the half-life of the IL-7 fusion protein. The modified IL-7 polypeptide is composed of the (a) first domain and the (b) second domain. The modified IL-7 polypeptide and the fusion protein are expressed in a higher yield than the wild-type IL-7 and shows increased stability. | 2021-10-21 |
20210324028 | IL-15 Variants and Uses Thereof - The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants. | 2021-10-21 |
20210324029 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY - Disclosed herein are stable peptide antagonists based on the consensus yc-subunit binding site to inhibit the activity of yc-cytokines. Such peptide antagonists are capable of inhibiting the activity of multiple yc-cytokine family members. The yc-family cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of yc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. | 2021-10-21 |
20210324030 | IL-2 VARIANTS WITH REDUCED BINDING TO IL-2 RECEPTOR ALPHA AND USES THEREOF - This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rβγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells. | 2021-10-21 |
20210324031 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME - Novel leptin and leptin-fusion protein-small molecule drug conjugates are disclosed, where conjugation takes place through the use of cleavable and non-cleavable linkers. The small molecules chemically linked to the protein carrier are imported into the specific leptin-responsive target tissue or cell through receptor-mediated endocytosis and released from the carrier protein through enzymatic cleavage of the linker-drug moiety or through lysosomal degradation of the carrier protein. Free drug then act to modify leptin receptor-triggered biochemical pathways that are altered in conditions of leptin-resistance. Drug will correct altered pathway allowing resensitization of receptor signaling. This can greatly aid in the resolution of pathologies either initiated at the onset of leptin resistance or exacerbated by it. | 2021-10-21 |
20210324032 | MANP Analogues - Analogues of an alternatively spliced form of atrial natriuretic peptide (MANP) that exhibit pGC-A gain of function and can be used to treat cardiorenal and metabolic disease are described herein. | 2021-10-21 |
20210324033 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEIN AND METHODS OF USE - The present disclosure relates to compositions of insulin-Fc fusion proteins and their use to treat feline diabetes. | 2021-10-21 |
20210324034 | T CELL RECEPTOR FOR IDENTIFYING AFP ANTIGEN - A T cell receptor (TCR) capable of specifically binding to a short peptide FMNKFIYEI derived from an AFP antigen. The antigen short peptide FMNKFIYEI can form a complex with HLA A0201 and be presented together with same to the cell surface. A nucleic acid molecule encoding the TCR, a vector comprising the nucleic acid molecule, and a cell that transduces the TCR. | 2021-10-21 |
20210324035 | COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES - Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2. | 2021-10-21 |
20210324036 | T CELL RECEPTORS - The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted FMNKFIYEI (158-166) SEQ ID NO: 1 peptide epitope derived from a Fetoprotein (AFP). Certain preferred TCRs of the invention demonstrate excellent binding characteristics and specificity profiles for this AFP epitope. T cell receptors of the invention may comprise at least one TCR alpha chain variable domain and/or at least one TCR beta chain variable domain, the alpha chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID NO: 2, and/or the beta chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID NO: 3. | 2021-10-21 |
20210324037 | CHIMERIC MOLECULES - The present invention relates to a method for simultaneous detection and enrichment of antigen-specific T cells and of the peptides specifically recognized by their T cell receptors (TCRs). The method also allows identification of T cell-specific antigens for in vivo and/or in vitro interventions including vaccination, induction of immunological tolerance, blocking of TCRs and MHC-mediated toxin delivery, for immunogenicity testing and other in vitro T-cell reactivity tests. The present invention also relates to the chimeric molecules used in said methods. | 2021-10-21 |
20210324038 | PD-L1 MUTANT HAVING IMPROVED BINDING AFFINITY FOR PD-1 - A PD-L1 mutant having improved binding affinity for PD-1 is disclosed. A method for preparing the PD-L1 variant and a method for screening the PD-L1 variant are also disclosed. The PD-L1 variant produced by substituting some amino acids in the sequence of wild-type PD-L1 with other optimal amino acids, achieving greatly improved affinity for PD-1. In addition, the possibility of immunogenicity can be reduced by the smallest possible number of the mutation sites. | 2021-10-21 |
20210324039 | BIFUNCTIONAL ANGIOGENESIS INHIBITOR AND USE THEREOF - The present invention relates to a bifunctional angiogenesis inhibitor, which has VEGF inhibitory activity and FGF inhibitory activity, and can inhibit VEGF and FGF dual factors-induced or high glucose-induced cell proliferation, cell migration, and/or lumen formation. The present invention also relates to the use of the bifunctional angiogenesis inhibitor in inhibiting retinal angiogenesis, such as diabetic retinopathy, age-related macular degeneration and the like. | 2021-10-21 |
20210324040 | TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND USES THEREOF - In certain aspects, the present disclosure relates to TβRII fusion polypeptides comprising a heterologous portion and a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders. | 2021-10-21 |
20210324041 | COMBINATION THERAPIES - The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity. | 2021-10-21 |
20210324042 | CHEMOKINE RESPONSIVE ACTIVATED NATURAL KILLER CELLS WITH SECONDARY HOMING ACTIVATION FOR VERIFIED TARGETS - Provided herein are modified NK-92 cells comprising a nucleic acid encoding C—C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C—C motif ligand 21 (CCL21), a nucleic acid encoding C—C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells. | 2021-10-21 |
20210324043 | ApoC-II Mimetic Peptides - The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide. | 2021-10-21 |
20210324044 | HETEROLOGOUS TARGETING PEPTIDE GRAFTED AAVS - The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same. | 2021-10-21 |
20210324045 | BULLFROG SKIN-DERIVED COLLAGEN, MATERIALS COMPRISING THEREOF, AND APPLICATIONS IN WOUND HEALING - Disclosed herein is a polymeric material that includes a crosslinked polymer matrix formed from a non-mammalian collagen and a crosslinking agent and/or a crosslinked polymer matrix formed from a non-mammalian collagen that has undergone self-crosslinking, wherein the non-mammalian collagen is type I collagen. Also disclosed herein is a wound dressing that incorporates said material and methods of treatment of a wound with said polymeric material or said wound dressing. | 2021-10-21 |
20210324046 | SYSTEMS AND METHODS FOR MANUFACTURE OF ENDOTOXIN-FREE HEMOGLOBIN-BASED DRUG SUBSTANCE - The present disclosure relates to methods and systems for manufacturing stabilized hemoglobin solutions. The methods and systems incorporate single use components for endotoxin-free formulation. The hemoglobin solutions may be substantially endotoxin-free and/or highly deoxygenated. | 2021-10-21 |
20210324047 | ANTIVIRUS PROTEINS HAVING A KRINGLE 5 SUBUNIT - COVID-19 results from the infection of the SARS-CoV-2 virus and has spread quickly to literally infected the world. Although coronavirus spike proteins can recognize a broad range of host cell-surface proteins, inhibiting spike protein binding to a survival factor called GRP78 results in a significant reduction in SARS-CoV-2 attachment, entry and replication in lung and kidney cells. This inhibition is accomplished with a novel type of inhibitor that potently blocks the binding of SARS-CoV-2 spike protein and whole virus to surface-bound GRP78. These novel GRP78 inhibitors also down regulate cytokines (IL10, IL6), immune co-inhibitory checkpoint proteins (PD-L1, B7H3, B7H4), and up regulate immune co-stimulatory proteins (MHC-II, CD-86) resulting in the reduction of the immune suppressive nature of infected lung alveolar epithelial cells in vitro and in vivo. Finally, these novel GRP78 inhibitors inhibit the hyperfibrinolysis of infected lung cells by reducing the activation of plasmin on cell surfaces. | 2021-10-21 |
20210324048 | COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF - The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure include the use of anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or prophylactically beneficial. | 2021-10-21 |
20210324049 | ANTIBODIES HAVING SPECIFICITY FOR THE ORF2I PROTEIN OF HEPATITIS E VIRUS AND USES THEREOF FOR DIAGNOSTIC PURPOSES - Hepatitis E virus (HEV) is annually responsible for 20 million infections with 3.4 million symptomatic cases and 70,000 deaths mainly occurring in less developed regions of the world. HEV is a non-enveloped virus containing a linear, single-stranded, positive-sense RNA genome that contains three open reading frames (ORFs), namely, ORF1, ORF2 and ORF3. ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Recently, 3 different forms of the ORF2 capsid protein were identified: infectious/intracellular ORF2 (ORF2i), glycosylated ORF2 (ORF2g), and cleaved ORF2 (ORF2c). The ORF2i protein, for which the precise sequence has been identified, is the form that is associated with infectious particles and thus antibodies having specificity for the ORF2i protein would be suitable for the diagnosis of HEV. The present fulfills this need by providing an antibody which binds to the ORF2i protein of hepatitis E virus and wherein said antibody does not bind to the ORF2g protein nor to the ORF2c of hepatitis E virus, and wherein the epitope of said antibody comprises at least one amino acid residue from amino acid residues 542 to 555 of SEQ ID NO: 1. | 2021-10-21 |
20210324050 | HUMAN MONOCLONAL ANTIBODIES THAT NEUTRALIZE PANDEMIC GII.4 NOROVIRUSES - The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a norovirus infection in a subject comprising (a) contacting a sample from the subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences; and (b) detecting norovirus in the sample by binding of the antibody or antibody fragment to a norovirus antigen in the sample. | 2021-10-21 |
20210324051 | ANTIBODY-MEDIATED NEUTRALIZATION OF MARBURG VIRUS - The present disclosure is directed to antibodies binding to Marburg virus (MARV) glycoprotein (GP) and methods of use therefore. | 2021-10-21 |
20210324052 | FORMULATIONS OF ANTI-RSV ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to stable formulations comprising antibodies or antigen-binding fragments thereof that bind to respiratory syncytial virus (RSV). Also provided are methods of preventing and/or treating RSV-related diseases with the formulations of the invention. | 2021-10-21 |
20210324053 | NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE - Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed. | 2021-10-21 |
20210324054 | BINDING PROTEIN OF NS1 PROTEIN - Provided is an isolated binding protein including an antigen-binding domain that binds to NS1 protein. The isolated binding protein includes specific heavy chain CDRs and light chain CDRs. The binding protein can specifically recognize and bind to NS1, and has relatively high sensitivity and specificity, thereby achieving the detection of dengue virus. Moreover, the binding protein is not required to be produced by inducing hybridoma cells in mouse abdominal cavity, and thus it is simple in production and has more stable antibody function. | 2021-10-21 |
20210324055 | Methods, Devices, Kits and Compositions for Detecting Tapeworm - Methods, devices, kits and compositions for detecting the presence or absence of one or more tapeworm coproantigens in a sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of tapeworm in a fecal sample from a mammal and may also be able to distinguish between different tapeworm species and in the presence of one or more infections with helminths (such as roundworm, hookworm, whipworm and heartworm), | 2021-10-21 |
20210324056 | METHODS OF TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE - Provided herein are methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of converting an amyloid positive subject having early Alzheimer's disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer's disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401. | 2021-10-21 |
20210324057 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING T CELL-DRIVEN DISEASES - Described herein are methods and compositions for treating graft versus host disease. Additionally, described herein are methods and compositions for treating diabetes. Aspects of the invention relates to administering to a subject an agent that inhibits LRRC8A as a monotherapy or in combination with additional therapeutics. | 2021-10-21 |